Literature DB >> 7739631

Facioscapulohumeral muscular dystrophy in the Dutch population.

G W Padberg1, R R Frants, O F Brouwer, C Wijmenga, E Bakker, L A Sandkuijl.   

Abstract

Extrapolating the figures from a previous study on FSHD in a province of The Netherlands to the entire Dutch population suggests that at present a nearly complete overview is obtained of all symptomatic kindred. In 139 families, dominant inheritance was observed in 97, a pattern compatible with germline mosaicism in 6, while sporadic cases were found in 36 families. A mutation frequency of 9.6% was calculated. Mental retardation and severe retinal vasculopathy were reported in low frequencies (1%). Early onset was seen more frequently in sporadic cases. Chromosome 4 linkage appeared excluded in 3 of 22 autosomal-dominant families. The clinical pictures in the linked and nonlinked families were identical.

Entities:  

Mesh:

Year:  1995        PMID: 7739631

Source DB:  PubMed          Journal:  Muscle Nerve Suppl


  42 in total

1.  De novo facioscapulohumeral muscular dystrophy: frequent somatic mosaicism, sex-dependent phenotype, and the role of mitotic transchromosomal repeat interaction between chromosomes 4 and 10.

Authors:  S M van der Maarel; G Deidda; R J Lemmers; P G van Overveld; M van der Wielen; J E Hewitt; L Sandkuijl; B Bakker; G J van Ommen; G W Padberg; R R Frants
Journal:  Am J Hum Genet       Date:  2000-01       Impact factor: 11.025

Review 2.  Facioscapulohumeral muscular dystrophy.

Authors:  Rabi Tawil
Journal:  Curr Neurol Neurosci Rep       Date:  2004-01       Impact factor: 5.081

3.  Mechanism and timing of mitotic rearrangements in the subtelomeric D4Z4 repeat involved in facioscapulohumeral muscular dystrophy.

Authors:  Richard J L F Lemmers; Petra G M Van Overveld; Lodewijk A Sandkuijl; Harry Vrieling; George W Padberg; Rune R Frants; Silvère M van der Maarel
Journal:  Am J Hum Genet       Date:  2004-05-20       Impact factor: 11.025

4.  FRG2, an FSHD candidate gene, is transcriptionally upregulated in differentiating primary myoblast cultures of FSHD patients.

Authors:  T Rijkers; G Deidda; S van Koningsbruggen; M van Geel; R J L F Lemmers; J C T van Deutekom; D Figlewicz; J E Hewitt; G W Padberg; R R Frants; S M van der Maarel
Journal:  J Med Genet       Date:  2004-11       Impact factor: 6.318

5.  Equal proportions of affected cells in muscle and blood of a mosaic carrier of facioscapulohumeral muscular dystrophy.

Authors:  Maria Manuela O Tonini; Richard J L F Lemmers; Rita C M Pavanello; Antonia M P Cerqueira; Rune R Frants; Silvere M van der Maarel; Mayana Zatz
Journal:  Hum Genet       Date:  2005-12-08       Impact factor: 4.132

6.  Population-based incidence and prevalence of facioscapulohumeral dystrophy.

Authors:  Johanna C W Deenen; Hisse Arnts; Silvère M van der Maarel; George W Padberg; Jan J G M Verschuuren; Egbert Bakker; Stephanie S Weinreich; André L M Verbeek; Baziel G M van Engelen
Journal:  Neurology       Date:  2014-08-13       Impact factor: 9.910

7.  Facioscapulohumeral muscular dystrophy: a prospective study of weakness and functional impairment.

Authors:  Joerg-Patrick Stübgen; Annette Stipp
Journal:  J Neurol       Date:  2010-03-30       Impact factor: 4.849

8.  Clinically Advanced p38 Inhibitors Suppress DUX4 Expression in Cellular and Animal Models of Facioscapulohumeral Muscular Dystrophy.

Authors:  Jonathan Oliva; Scott Galasinski; Amelia Richey; Amy E Campbell; Marvin J Meyers; Neal Modi; Jun Wen Zhong; Rabi Tawil; Stephen J Tapscott; Francis M Sverdrup
Journal:  J Pharmacol Exp Ther       Date:  2019-06-12       Impact factor: 4.030

9.  FSHD region gene 1 (FRG1) is crucial for angiogenesis linking FRG1 to facioscapulohumeral muscular dystrophy-associated vasculopathy.

Authors:  Ryan D Wuebbles; Meredith L Hanel; Peter L Jones
Journal:  Dis Model Mech       Date:  2009-04-21       Impact factor: 5.758

10.  Muscular dystrophy candidate gene FRG1 is critical for muscle development.

Authors:  Meredith L Hanel; Ryan D Wuebbles; Peter L Jones
Journal:  Dev Dyn       Date:  2009-06       Impact factor: 3.780

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.